Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Endocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancers|Neuroendocrine Tumors|Multiple Myeloma
Interventions: DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin|BIOLOGICAL: Individual Patient TCR-Transduced PBL|DRUG: Pembrolizumab (KEYTRUDA )
Sponsor: National Cancer Institute (NCI)